The Pharma Letter Pharmaletter News Articles
BRIEF—AbbVie in I-O deal with Californian biotech
US drugmaker AbbVie has announced an immuno-oncology (I-O) research collaboration with Harpoon Therapeutics,…
BRIEF—CEO of regenerative medicine company resigns
Antony Odell is resigning from his role as chief executive of UK-based regenerative medicine company…
Vir announces multi-billion dollar agreements to boost R&D pipeline
San Franciscan firm Vir Biotechnology has announced a series of strategic deals aimed at boosting its…
US bid to repeal 2016 law seen as preventing aggressive DEA enforcement of opioid distributors
US President Donald Trump on Tuesday said his nominee to head the Office of National Drug Control Policy,…
WHO prequalification for Synflorix pneumococcal vaccine four-dose vial
The World Health Organization (WHO) has awarded prequalification for the new four-dose vial presentation…
Lilly and Germany's CureVac agree I-O deal worth up to $2 billion
Indianapolis, USA-based Eli Lilly and privately-held German firm CureVac have announced a global immuno-oncology…
Battle lines drawn in EU SPC battle
Generic drugmakers and research-based pharma companies are used to facing each other in patent rows that…
GP Labs plans production of cancer drugs in Russia
The GP Laboratories, a supplier of UK licensed branded and generic pharmaceuticals, has announced its…
BRIEF—Jan van de Winkel becomes chairman of Hookipa
Viennese immunotherapy specialist Hookipa Biotech has appointed a new chairman, Dr Jan van de Winkel,…
BRIEF—Priority review status for first PARP inhibitor application outside of ovarian cancer
The UK’s AstraZeneca and New Jersey-based Merck & Co have announced the US FDA will review an application…
As patent due to expire, AHF calls on Gilead for 90% price cut on tenofovir-based drugs
Noting that with the patent ending and generics looming, USA-based global AIDS organization AIDS Healthcare…
BRIEF—Novartis publishes positive long-term data in rare blood disorder
Switzerland’s Novartis has published long-term study safety and efficacy data from the EXTEND study…
Takeda starts production of anti-cancer drug in Russia
Takeda Pharmaceutical, together with Russia’s JSC Pharmstandard, announced the beginning of production…
BRIEF -- Latest QuintilesIMS Institute analysis on Orphan drugs
In the USA, the National Institutes for Health estimates that between 25 million and 30 million people…
BRIEF—Takeda in NASH deal with HemoShear
Takeda Pharmaceutical and privately-held US biotech HemoShear Therapeutics have announced a partnership…
BRIEF—Latest Opdivo sBLA accepted by FDA
The US Food and Drug Administration (FDA) has accepted for priority review Bristol-Myers Squibb’s supplemental…
BRIEF—Entyvio analyses show improvements in ulcerative colitis or Crohn’s disease
Takeda Pharmaceutical has announced the presentation of data suggesting early symptomatic improvement…
Confirmed merger with Amneal sends Impax stock sliding
Shares in Impax Laboratories were worth 10% less at $18 after Tuesday morning’s trading.
Teva files potential blockbuster migraine drug for FDA approval
Teva Pharmaceutical Industries has submitted a Biologics License Application (BLA) to the US Food and…
Underlying economic data show drug prices are not soaring
While headlines tend to focus on high drug prices, particularly when price gouging is involved, the underlying…
Pfizer spin-off SpringWorks Therapeutics is an encouraging sign for innovation in big pharma
In this week's feature, Michael Jewell, the healthcare partner at Cavendish Corporate Finance, looks…
Promotion for new boy Riva at Gilead Sciences
Just a few months after joining the US biotech major, Alessandro Riva has received a promotion.
BRIEF --EMA publishes Business Continuity Plan for Brexit
The European Medicines Agency has published its Brexit Preparedness Business Continuity Plan. The plan,…
BRIEF—J&J’s quarter tops estimates
Presenting its latest quarterly results, US healthcare giant Johnson & Johnson posted adjusted earnings…
J&J jumps after pharma sales help to beat third-qtr estimates
Johnson & Johnson, the world’s largest healthcare company, looked set to open trading on Tuesday around…
Impact Biomedicines to resurrect abandoned myelofibrosis drug
US biotech start-up Impact Biomedicines announced its launch to pioneer the development of life-changing…
US District Court invalidates Restasis patents
The US District Court for the Eastern District of Texas has issued an adverse trial decision finding…
Around of half global pharma revenues comprised of MAb products, new report finds
The overall industry pipeline for monoclonal antibodies (MAbs) has reached an unprecedented scale, now…
Mutabilis joins European project supporting antiobiotics research
France's Mutabilis, a spinout from INSERM focused on new antibiotics, has announced it is participating…
Plasticell in deal with pharma major to produce hematopoietic cells from iPSCs
UK biotech Plasticell has entered into a collaboration with pharma major GlaxoSmithKline to use its combinatorial…
Feed Fetched by RSS Dog.